Mitochondrial carrier homolog 2 is necessary for AML survival
Author(s) -
Dilshad H. Khan,
Michael Mullokandov,
Yan Wu,
Véronique Voisin,
Marcela Gronda,
Rose Hurren,
Xiaoming Wang,
Neil MacLean,
Danny V. Jeyaraju,
Yulia Jitkova,
G. Wei Xu,
Rob C. Laister,
Ayesh K. Seneviratne,
Zachary Blatman,
Troy Ketela,
Gary D. Bader,
Sajid A. Marhon,
Daniel D. De Carvalho,
Mark D. Minden,
Atan Gross,
Aaron D. Schimmer
Publication year - 2020
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019000106
Subject(s) - mitochondrion , stem cell , biology , gene knockdown , microbiology and biotechnology , myeloid , cancer research , myeloid leukemia , gene , genetics
Through a clustered regularly insterspaced short palindromic repeats (CRISPR) screen to identify mitochondrial genes necessary for the growth of acute myeloid leukemia (AML) cells, we identified the mitochondrial outer membrane protein mitochondrial carrier homolog 2 (MTCH2). In AML, knockdown of MTCH2 decreased growth, reduced engraftment potential of stem cells, and induced differentiation. Inhibiting MTCH2 in AML cells increased nuclear pyruvate and pyruvate dehydrogenase (PDH), which induced histone acetylation and subsequently promoted the differentiation of AML cells. Thus, we have defined a new mechanism by which mitochondria and metabolism regulate AML stem cells and gene expression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom